Focused on precision oncology and rare genetic diseases, this biotech reported a significant insider sale amid strong one-year stock gains.

TheFly reported on December 15 that Barclays raised its price target for TWST from $37 to $39 while maintaining an Overweight ...

Abstract: Unlike Quality by Testing approach, where products were tested only after drug manufacturing, Quality by Design (QbD) is a proactive control quality paradigm, which handles risks from the ...